32
https://pubmed.ncbi.nlm.nih.gov/38115933
The abstract reports on a new targeted therapy, futibatinib, for intrahepatic cholangiocarcinoma, with no conflicts of interest declared by the authors.
“New Targeted Therapy, Futibatinib, for Intrahepatic Cholangiocarcinoma: A Conflict-Free Study”
